Related Experiment Video

Updated: Aug 9, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway

Deborah Chirnomas1, Toshiyasu Taniguchi, Michelle de la Vega

  • 1Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA.

Molecular Cancer Therapeutics
|May 2, 2006
PubMed

Insights

Curcumin, a natural compound, can overcome cisplatin resistance by inhibiting the Fanconi anemia (FA)/BRCA DNA repair pathway. This approach sensitizes ovarian and breast cancer cells to chemotherapy, offering a new strategy for cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cisplatin resistance is a significant challenge in cancer therapy, often mediated by DNA damage response pathways like Fanconi anemia (FA)/BRCA.
  • The FA/BRCA pathway is crucial for repairing DNA cross-links induced by platinum-based chemotherapy agents such as cisplatin.

Purpose of the Study:

  • To develop a cell-based screening strategy to identify small-molecule inhibitors of the FA/BRCA pathway.
  • To investigate whether inhibiting the FA/BRCA pathway can restore sensitivity to platinum agents in resistant cancer cells.

Main Methods:

  • A high-throughput cell-based screen was employed to identify inhibitors of the FA/BRCA pathway.
  • The efficacy of identified inhibitors, particularly curcumin, was evaluated in sensitizing ovarian and breast cancer cell lines to cisplatin.

Main Results:

  • Four small-molecule inhibitors of the FA/BRCA pathway were identified, including three protein kinase inhibitors and the natural compound curcumin.
  • Curcumin was confirmed to inhibit FANCD2 monoubiquitination, a key step in the FA/BRCA pathway.
  • Curcumin treatment sensitized cisplatin-resistant ovarian and breast cancer cell lines to cisplatin, inducing apoptotic cell death.

Conclusions:

  • The study presents an efficient method for discovering compounds that can overcome cisplatin resistance by targeting the FA/BRCA pathway.
  • Curcumin demonstrates potential as a sensitizing agent to enhance the efficacy of platinum-based chemotherapy in specific cancer types.
  • Inhibiting DNA repair pathways offers a promising strategy to improve outcomes for patients with cisplatin-resistant cancers.

More Related Videos

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity04:20

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity

Published on: February 9, 2024

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...